دورية أكاديمية
The effect of nicorandil on cardiac function and clinical outcomes in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a randomised trial.
| العنوان: | The effect of nicorandil on cardiac function and clinical outcomes in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a randomised trial. |
|---|---|
| المؤلفون: | Choe JC; Department of Internal Medicine, Division of Cardiology, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea., Oh JH; Department of Internal Medicine, Division of Cardiology, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea., Lee HC; Department of Internal Medicine, Division of Cardiology, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea., Lee JW; Department of Radiology, Pusan National University Hospital, Busan, Republic of Korea., Park TS; Department of Internal Medicine, Division of Cardiology, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea., Park JH; Department of Internal Medicine, Division of Cardiology, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea., Kim E; Department of Internal Medicine, Division of Cardiology, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea., Kim MS; Department of Thoracic and Cardiovascular Surgery, Pusan National University Hospital, Busan, Republic of Korea., Ahn J; Department of Internal Medicine, Division of Cardiology, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea., Park JS; Department of Internal Medicine, Division of Cardiology, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea., Lee HW; Department of Internal Medicine, Division of Cardiology, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea., Choi JH; Department of Internal Medicine, Division of Cardiology, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea., Cha KS; Department of Internal Medicine, Division of Cardiology, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea. |
| المصدر: | Acta cardiologica [Acta Cardiol] 2023 Oct; Vol. 78 (8), pp. 880-888. Date of Electronic Publication: 2023 Mar 21. |
| نوع المنشور: | Randomized Controlled Trial; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 0370570 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1784-973X (Electronic) Linking ISSN: 00015385 NLM ISO Abbreviation: Acta Cardiol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2017- : London : Taylor & Francis Original Publication: Bruxelles : Acta Medica Belgica |
| مواضيع طبية MeSH: | ST Elevation Myocardial Infarction*/therapy , ST Elevation Myocardial Infarction*/drug therapy , Percutaneous Coronary Intervention* , Myocardial Infarction*/therapy , Myocardial Infarction*/drug therapy, Humans ; Nicorandil/therapeutic use ; Prospective Studies ; Treatment Outcome |
| مستخلص: | Background: We investigated the effect of nicorandil on infarct size, cardiac function assessed by cardiac magnetic resonance imaging (CMR) and outcomes in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI). Methods: In a prospective, randomised, controlled trial, 83 patients with STEMI receiving primary PCI were randomised into the nicorandil ( n = 40) or placebo ( n = 43) groups. Nicorandil was administered in the emergency room before primary PCI as an intravenous bolus of 4 mg followed by a continuous infusion of 6 mg/h for 24 h and as 2-mg intracoronary injections prior to balloon dilatation and coronary stenting. Nicorandil was continued orally at 10-20 mg/d for 6 months. Infarct size and cardiac function were measured by CMR at 5 d and 6 months after primary PCI. Furthermore, major adverse cardiac events (MACEs) including all-cause death, nonfatal myocardial infarction (MI), any revascularisation, stroke, and definite/probable stent thrombosis (ST) were compared. Results: There were no significant differences in baseline clinical characteristics between the groups. Infarct size at baseline and 6 months as well as infarct size changes during 6 months as measured by CMR were similar between the groups. Similarly, other CMR parameters were comparable at baseline and 6 months between the groups. MACEs occurred in four patients (4.8%) during 6 months. No significant difference in the risk of MACEs was observed between the groups. Conclusions: Treatment with nicorandil for 6 months after primary PCI was not associated with any improvement in infarct size, CMR-determined cardiac function, and outcomes in STEMI patients. |
| فهرسة مساهمة: | Keywords: Nicorandil; ST-segment elevation myocardial infarction; cardiac function; cardiac magnetic resonance; clinical outcome; primary percutaneous coronary intervention |
| المشرفين على المادة: | 260456HAM0 (Nicorandil) |
| تواريخ الأحداث: | Date Created: 20230321 Date Completed: 20231023 Latest Revision: 20231023 |
| رمز التحديث: | 20240829 |
| DOI: | 10.1080/00015385.2022.2129592 |
| PMID: | 36942830 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1784-973X |
|---|---|
| DOI: | 10.1080/00015385.2022.2129592 |